Therapeutic approaches to the modulation of apoptosis

Essays in Biochemistry

Volumn 39, Issue , 2003, Pages 131-153

  Murphy, Finbarr J ^a   Seery, Liam T ^a   Hayes, Ian ^a  

^a EiRx Therapeutics Ltd   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

4 [2 [4 (3,10 DIBROMO 8 CHLORO 6,11 DIHYDRO 5H BENZO[5,6]CYCLOHEPTA[1,2 B]PYRIDIN 11 YL) 1 PIPERIDINYL] 2 OXOETHYL] 1 PIPERIDINECARBOXAMIDE; 6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; 6 [3 (1 ADAMANTYL) 4 HYDROXYPHENYL] 2 NAPHTHOIC ACID; 7 HYDROXYSTAUROSPORINE; ARSENIC TRIOXIDE; AUGMEROSEN; CASPASE INHIBITOR; FENRETINIDE; GLEEVAC; HISTONE DEACETYLASE INHIBITOR; IBRITUMOMAB TIUXETAN; IDN 6556; IDN 6734; IMATINIB; MAJOR HISTOCOMPATIBILITY ANTIGEN; MONOCLONAL ANTIBODY; ONYX 015; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOTOFRIN; PIVANEX; PROTEASOME INHIBITOR; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; R 115777; REACTIVE OXYGEN METABOLITE; RETINOIC ACID; RITUXIMAB; SCH 58500; TOSITUMOMAB I 131; TRASTUZUMAB; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; UNINDEXED DRUG; VX 799;

ABDOMINAL DISCOMFORT; APOPTOSIS; BREAST CANCER; CANCER CHEMOTHERAPY; CARCINOGENESIS; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DISEASE COURSE; DRUG MECHANISM; DRUG TARGETING; ESOPHAGUS CARCINOMA; FATIGUE; FOOD AND DRUG ADMINISTRATION; GLIOMA; HEAD AND NECK CARCINOMA; HEADACHE; HEART INFARCTION; HUMAN; INFLAMMATION; INVASIVE CARCINOMA; LEUKEMIA; LIVER DISEASE; LUNG NON SMALL CELL CANCER; MELANOMA; MULTIPLE MYELOMA; NAUSEA; NONHODGKIN LYMPHOMA; NONHUMAN; ONCOLOGY; OVARY CARCINOMA; PHOTODYNAMIC THERAPY; PROMYELOCYTIC LEUKEMIA; REGULATORY MECHANISM; REVIEW; SEPSIS; SKIN DISEASE; TARGET CELL; VOMITING;

EID: 0344584830     PISSN: 00711365     EISSN: None     Source Type: Journal    
DOI: 10.1042/bse0390131     Document Type: Review

References (52)

1. Endres, M., Namura, S., Shimizu-Sasamata, M., Waeber, C., Zhang, L., Gomez-Isla, T., Hyman, B.T. & Moskowitz, M.A. (1998) Attenuation of delayed neuronal death after mild focal ischemia in mice by inhibition of the caspase family. J. Cereb. Blood Flow Metab. 18, 238-247
2. Cursio, R., Gugenheim, J., Ricci, J.E., Crenesse, D., Rostagno, P., Maulon, L., Saint-Paul, M.C., Ferrua, B. & Auberger, A.P. (1999) A caspase inhibitor fully protects rats against lethal normothermic liver ischemia by inhibition of liver apoptosis. FASEB J. 13, 253-261
3. Mocanu, M.M., Baxter, G.F. & Yellon, D.M. (2000) Caspase inhibition and limitation of myocardial infarct size: protection against lethal reperfusion injury. Br. J. Pharmacol. 130, 197-200
4. Hotchkiss, R.S., Chang, K.C., Swanson, P.E., Tinsley, K.W., Hui, J.J., Klender, P., Xanthoudakis, S., Roy, S., Black, C., Grimm, E. et al. (2000) Caspase inhibitors improve survival in sepsis: a critical role of the lymphocyte. Nat. Immunol. 1, 496-501
5. Leist, M. & Jaattela M. (2001) Four deaths and a funeral: from caspases to alternative mechanisms. Nat. Rev. Mol. Cell Biol. 2, 589-598
6. Hu, S., Snipas, S.J., Vincenz, C., Salvesen, G. & Dixit, V.M. (1998) Caspase-14 is a novel developmentally regulated protease. J. Biol. Chem. 273, 29648-29653
7. de Bilbao, F., Guarin, E., Nef, P., Vallet, P., Giannakopoulos, P. & Dubois-Dauphin M. (1999) Postnatal distribution of cpp32/caspase 3 mRNA in the mouse central nervous system: an in situ hybridization study. J. Comp. Neurol. 409, 339-357
8. Donovan, M. & Cotter, T.G. (2002) Caspase-independent photoreceptor apoptosis in vivo and differential expression of apoptotic protease activating factor-1 and caspase-3 during retinal development. Cell Death Differ. 9, 1220-1231
9. Reed, J.C. (1999) Mechanisms of apoptosis avoidance in cancer. Curr. Opin. Oncol. 11, 68-75
10. Wang, J.L, Liu, D., Zhang, Z.J., Shan, S., Han, X., Srinivasula, S.M., Croce, C.M., Alnemri, E.S. & Huang, Z. (2000) Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. Proc. Natl. Acad. Sci. U.S.A. 97, 7124-7129
11. Komarov, P.G., Komarova, E.A., Kondratov, R.V., Christov-Tselkov, K., Coon, J.S., Chernov, M.V. & Gudkov, A.V. (1999) A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science 285, 1733-1737
12. Duan, W., Zhu, X., Ladenheim, B., Yu, Q.S., Guo, Z., Oyler, J., Cutler, R.G., Cadet, J.L., Greig, N.H. & Mattson, M.P. (2002) p53 inhibitors preserve dopamine neurons and motor function in experimental parkinsonism. Ann. Neurol. 52, 597-606
13. Keer, H.N., Reid, T. & Sreedharan, S. (2002) Pivanex activity in refractory non-small cell lung cancer, a phase II study. In 38th Annual Meeting of the American Society of Clinical Oncology (ASCO), abstract 1253
14. Batova, A., Shao, L.E., Diccianni, M.B., Yu, A.L., Tanaka, T., Rephaeli, A., Nudelman, A. & Yu, J. (2002) The histone deacetylase inhibitor AN-9 has selective toxicity to acute leukemia and drug-resistant primary leukemia and cancer cell lines. Blood 100, 3319-3324
15. Hideshima, T., Richardson, P., Chauhan, D., Palombella, V.J., Elliott, P.J., Adams, J. & Anderson, K.C. (2001) The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 61, 3071-3076
16. LeBlanc, R., Catley, L.P., Hideshima, T., Lentzsch, S., Mitsiades, C.S., Mitsiades, N., Neuberg, D., Goloubeva, O., Pien, C.S., Adams, J. et al. (2002) Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res. 62, 4996-5000
17. Hideshima, T. & Anderson, K.C. (2002) Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat. Rev. Cancer 2, 927-937
18. Hideshima, T., Chauhan, D., Richardson, P., Mitsiades, C., Mitsiades, N., Hayashi, T., Munshi, N., Dang, L., Castro, A., Palombella, V. et al. (2002) NF-kappa B as a therapeutic target in multiple myeloma. J. Biol. Chem. 277, 16639-16647
19. Vivanco, I. & Sawyers, C.L. (2002) The phosphatidylinositol 3-kinase-AKT pathway in human cancer. Nat. Rev. Cancer 2, 489-501
20. Sato, S., Fujita, N. & Tsuruo T. (2002) Interference with PDK1-Akt survival signaling pathway by UCN-01 (7-hydroxystaurosporine). Oncogene 21, 1727-1738
21. Karp, J.E., Lancet, J.E., Kaufmann, S.H., End, D.W., Wright, J.J., Bol, K., Horak, I., Tidwell, M.L., Liesveld, J., Kottke, T.J. et al. (2001) Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase I clinical-laboratory correlative trial. Blood 97, 3361-3369
22. Le Gouill, S., Pellat-Deceunynck, C., Harousseau, J.L., Rapp, M.J., Robillard, N., Bataille, R. & Amiot, M. (2002) Farnesyl transferase inhibitor R115777 induces apoptosis of human myeloma cells. Leukemia 16, 1664-1667
23. Mauro, M.J., O'Dwyer, M.E. & Druker, B.J. (2001) ST1571, a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia: validating the promise of molecularly targeted therapy. Cancer Chemother. Pharmacol. 48, suppl. 1, S77-S78
24. Kantarjian, H., Sawyers, C., Hochhaus, A., Guilhot, F., Schiffer, C., Gambacorti-Passerini, C., Niederwieser, D., Resta, D., Capdeville, R., Zoellner, U. et al. (2002) Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N. Engl. J. Med. 346, 645-652
25. Myers, J.N., Holsinger, F.C., Bekele, B.N., Li, E., Jasser, S.A., Killion, J.J. & Fidler, I.J. (2002) Targeted molecular therapy for oral cancer with epidermal growth factor receptor blockade: a preliminary report. Arch. Otolaryngol. Head Neck Surg. 128, 875-879
26. Baker, C.H., Kedar, D., McCarty, M.F., Tsan, R., Weber, K.L., Bucana, C.D. & Fidler, I.J. (2002) Blockade of epidermal growth factor receptor signaling on tumor cells and tumor-associated endothelial cells for therapy of human carcinomas. Am. J. Pathol. 161, 929-938
27. Medema, J.P., Scaffidi, C., Kischkel, F.C., Shevchenko, A., Mann, M., Krammer, P.H. & Peter, M.E. (1997) FLICE is activated by association with the CD95 death-inducing signaling complex (DISC). EMBO J. 16, 2794-2804
28. Nagane, M., Pan, G., Weddle, J.J., Dixit, V.M., Cavenee, W.K. & Huang, H.J. (2000). Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo. Cancer Res. 60, 847-853
29. Jo, M., Kim, T.H., Seol, D.W., Esplen, J.E., Dorko, K., Billiar, T.R. & Strom, S.C. (2000) Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat. Med. 6, 564-567
30. Lawrence, D., Shahrokh, Z., Marsters, S., Achilles, K., Shih, D., Mounho, B., Hillan, K., Totpal, K., DeForge, L, Schow, P. et al. (2001) Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat. Med. 7, 383-385
31. Kelley, S.K., Harris, L.A., Xie, D., Deforge, L., Totpal, K., Bussiere, J. & Fox, J.A. (2001) Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety. J. Pharmacol. Exp. Ther. 299, 31-38
32. Choi, C., Kutsch, O., Park, J., Zhou, T., Seol, D.W. & Benveniste, E.N. (2002) Tumor necrosis factor-related apoptosis-inducing ligand induces caspase-dependent interleukin-8 expression and apoptosis in human astroglioma cells. Mol. Cell. Biol. 22, 724-736
33. Stockmeyer, B., Schiller, M., Repp, R., Lorenz, H.M., Kalden, J.R., Gramatzki, M. & Valerius T. (2002) Enhanced killing of B lymphoma cells by granulocyte colony-stimulating factor-primed effector cells and HulD10 - a humanized human leucocyte antigen DR antibody. Br. J. Haematol. 118, 959-967
34. Nagy, Z.A., Hubner, B., Lohning, C., Rauchenberger, R., Reiffert, S., Thomassen-Wolf, E., Zahn, S., Leyer, S., Schier, E.M., Zahradnik, A. et al. (2002). Fully human, HLA-DR-specific monoclonal antibodies efficiently induce programmed death of malignant lymphoid cells. Nat. Med. 8, 801-807
35. Yakes, F.M., Chinratanalab, W., Ritter, C.A., King, W., Seelig, S. & Arteaga, C.L. (2002) Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt 1s required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res. 62, 4132-4141
36. Lee, S., Yang, W., Lan, K.H., Sellappan, S., Klos, K., Hortobagyi, G., Hung, M.C. & Yu, D. (2002) Enhanced sensitization to taxol-induced apoptosis by herceptin pretreatment in ErbB2-overexpressing breast cancer cells. Cancer Res. 62, 5703-5710
37. Opalinska, J.B. & Gewirtz, A.M. (2002) Nucleic-acid therapeutics: basic principles and recent applications. Nat. Rev. Drug Discov. 1, 503-514
38. Cotter, F.E. (1999) Antisense oligonucleotides for haematological malignancies. Haematologica 84, suppl. EHA-4, 19-22
39. Marcucci, G., Byrd, J.C., Dai, G., Klisovic, M.I., Kourlas, P.J., Young, D.C., Cataland, S.R., Fisher, D.B., Lucas, D., Chan, K.K. et al. (2003) Phase I and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia. Blood 101, 425-432
40. Buller, R.E., Shahin, M.S., Horowitz, J.A., Runnebaum, I.B., Mahavni, V., Petrauskas, S., Kreienberg, R., Karlan, B., Slamon, D. & Pegram M. (2002) Long term follow-up of patients with recurrent ovarian cancer after Ad p53 gene replacement with SCH 58500. Cancer Gene Ther. 9, 567-572
41. Khuri, F.R., Nemunaitis, J., Ganly, I., Arseneau, J., Tannock, I.F., Romel, L., Gore, M., Ironside, J., MacDougall, R.H., Heise, C. et al. (2000) A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat. Med. 6, 879-885
42. Anderson, C.Y., Freye, K., Tubesing, K.A., Li, Y.S., Kenney, M.E., Mukhtar, H. & Elmets, C.A. (1998) A comparative analysis of silicon phthalocyanine photosensitizers for in vivo photodynamic therapy of RIF-1 tumors in C3H mice. Photochem. Photobiol. 67, 332-336
43. Fontana, J.A. & Rishi, A.K. (2002) Classical and novel retinoids: their targets in cancer therapy. Leukemia 16, 463-472
44. Li, Y., Dawson, M.I., Agadir, A., Lee, M.O., Jong, L., Hobbs, P.D. & Zhang, X.K. (1998) Regulation of RAR beta expression by RAR-and RXR-selective retinoids in human lung cancer cell lines: effect on growth inhibition and apoptosis induction. Int. J. Cancer 75, 88-95
45. Marchetti, P., Zamzami, N., Joseph, B., Schraen-Maschke, S., Mereau-Richard, C., Costantini, P., Metivier, D., Susin, S.A., Kroemer, G. & Formstecher P. (1999) The novel retinoid 6-[3-(1-adamantyl)-4- hydroxyphenyl]-2-naphtalene carboxylic acid can trigger apoptosis through a mitochondrial pathway independent of the nucleus. Cancer Res. 59, 6257-6266
46. Marchetti, P., Mortier, L., Beauvillain, V. & Formstecher, P. (2002) Are mitochondria targets of anticancer drugs responsible for apoptosis? Ann. Biol. Clin. (Paris) 60, 391-403
47. Lovat, P.E., Ranalli, M., Bernassola, F., Tilby, M., Malcolm, A.J., Pearson, A.D., Piacentini, M., Melino, G. & Redfern, C.P. (2000) Synergistic induction of apoptosis of neuroblastoma by fenretinide or CD437 in combination with chemotherapeutic drugs. Int. J. Cancer 88, 977-985
48. Veronesi, U., De Palo, G., Marubini, E., Costa, A., Formelli, F., Mariani, L., Decensi, A., Camerini, T., Del Turco, M.R., Di Mauro, M.G. et al. (1999) Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer. J. Natl. Cancer Inst. 91, 1847-1856
49. 3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 89, 3354-3360
50. Woo, S.H., Park, I.C., Park, M.J., Lee, H.C., Lee, S.J., Chun, Y.J., Lee, S.H., Hong, S.I. & Rhee, C.H. (2002) Arsenic trioxide induces apoptosis through a reactive oxygen species-dependent pathway and loss of mitochondrial membrane potential in HeLa cells. Int. J. Oncol. 21, 57-63
51. Yi, J., Gao, F., Shi, G., Li, H., Wang, Z., Shi, X. & Tang X. (2002). The inherent cellular level of reactive oxygen species: one of the mechanisms determining apoptotic susceptibility of leukemic cells to arsenic trioxide. Apoptosis 7, 209-215
52. Soignet, S.L., Frankel, S.R., Douer, D., Tallman, M.S., Kantarjian, H., Calleja, E., Stone, R.M., Kalaycio, M., Scheinberg, D.A., Steinherz, P. et al. (2001) United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J. Clin. Oncol. 19, 3852-3860